The Investigator-Initiated Study (IIS) Program for Diabetes aims at advancing the delivery of quality healthcare by supporting investigator original research that will enhance the understanding of disease entities and their treatment. This program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research.
1. Prediabetes and Pathophysiology New therapeutic options of linagliptin in prediabetes and type 2 diabetes
|
2. Patients and Care
|
|
3. Incretin Effects
Effects of incretin mimetics on mechanism and actions of relevant biological pathways
|
4. DPP-4 Inhibition
New insights in the pathophysiology and biochemical pathways of DPP-4 inhibition focusing on an ubiquitary enzyme and transfer into clinical reality
|
|
5. Renal, Cardiovascular and further Complications of Diabetes
|
6. Alpha- and Beta-Cell Function Effects of linagliptin on alpha- and beta-cells in terms of function, survival rate and regeneration with focus on new biomarker concepts and/or (im)balance of insulin and glucagon secretion |
Not to restrict scientific creativity other research focus areas will be considered as well.
Please fill out the relevant form and send it to Boehringer Ingelheim:
Info.IIS-Diabetes@boehringer-ingelheim.com
After we received your online-application a local representative of
Boehringer Ingelheim will contact you.